Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)

Overview of attention for article published in International Journal of Hematology, September 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 7,211 followers.

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years. #CML . https://t.co/qFlMeCzG1N https://t.co/7l57dT0bjx

Reply Repost Favourite